Reuters Summit-UPDATE 1-Edwards sees sales growth over 10 pct

(For other news from the Reuters Health Summit, click here)

* Sees profit margins continuing to improve

* Sees transcatheter valve market share rising (Adds details, stock price, bylines)

By Debra Sherman and Susan Kelly

NEW YORK, Nov 11 (Reuters) - Edwards Lifesciences Corp's (EW.N) sales growth will likely top 10 percent in 2010, driven by robust demand for its heart valves, critical-care products and cardiac surgery systems, CEO Michael Mussallem said on Wednesday.

"We are tracking above the 10 percent rate ... and would expect that to continue," Mussallem said at the Reuters Health Summit in New York. "I do not think Wall Street will be disappointed."

The forecast excludes the impact of foreign exchange and divestitures.

Mussallem said he expects Edwards' profit margins to continue to improve, rising by a half to a full percentage point next year, in line with recent trends.

The company pioneered a technique for replacing aortic valves through a catheter, avoiding the need for open-heart surgery. The product, known as the transcatheter valve, has increased its market share in Europe in recent quarters, Mussallem said. He expects the launch of the next-generation product to take more market share next year.